QN 302
Alternative Names: QN-302; SOP-1812Latest Information Update: 18 Jul 2025
At a glance
- Originator University College London
- Developer Qualigen Therapeutics
- Class Antineoplastics; Morpholines; Phenanthrolines; Pyrrolidines; Small molecules
- Mechanism of Action G-Quadruplex modulators; Transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 16 Jul 2025 Qualigen Therapeutics has patent protection for QN 302 in the Europe
- 08 Apr 2024 Qualigen Therapeutics has patents pending and patent protection for QN 302 in USA, Europe, Australia, Canada, China, Hong Kong, India, Japan, Korea and Russia
- 05 Apr 2024 Interim adverse events and efficacy data from a phase-I trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)